A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

Table 1 The demographic and comorbid medical disorders at index date, before and after propensity score weighting, among hypertensive and diabetic patients who were prescribed with either angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)

	Propensity score weighting
	Before			After
	ACEi (n = 6898)	ARB (n = 12,758)	Standardized mean difference	ACEi (n = 6898)	ARB (n = 12,758)	Standardized mean difference
Duration from DM to index date^a (years)	3.07 ± 3.15	3.69 ± 3.33	−0.1931	3.17 ± 3.15	3.08 ± 2.26	−0.0032
Age (years) (mean ± SD)	61.5 ± 13.0	62.4 ± 12.8	−0.0711	61.5 ± 13.0	61.3 ± 9.7	0.0183
Age group			0.0944			0.0053
20–49 (%)	20.9	17.2		20.9	21.0
50–64 (%)	39.4	40.3		39.4	39.5
65+ (%)	39.7	42.4		39.7	39.5
Male sex	59.5 %	53.1 %	0.1271	59.5 %	59.5 %	−0.0016
Congestive heart failure	4.51 %	4.85 %	−0.0163	4.51 %	4.51 %	−0.0000
Stroke	12.73 %	14.70 %	−0.0572	12.73 %	12.73 %	−0.0000
Malignant dysrhythmia	0.45 %	0.49 %	−0.0054	0.45 %	0.45 %	0.0004
Cardiogenic shock	0.32 %	0.23 %	0.0176	0.32 %	0.33 %	−0.0025
MI/PCI	5.00 %	4.56 %	0.0206	5.00 %	4.98 %	0.0010
CABG	0.46 %	0.60 %	−0.0192	0.46 %	0.46 %	0.0012
Thrombolysis therapy	0.25 %	0.24 %	0.0023	0.25 %	0.24 %	0.0018
Hyperlipidemia	54.54 %	59.81 %	−0.1066	54.54 %	54.68 %	−0.0029
Chronic kidney disease	13.51 %	16.73 %	−0.0901	13.51 %	13.51 %	0.0001

DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, MI myocardial infarction, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery
^aIndex date was the date first prescribed either ACEi or ARB

ISSN: 1475-2840